Minerva Neurosciences, Inc. (NERV)

Market Cap	326.29M +2,712.8%
Revenue (ttm)	n/a
Net Income	-293.42M
EPS	-34.67
Shares Out	43.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,259,192
Open	8.00
Previous Close	8.07
Day's Range	7.52 - 8.17
52-Week Range	1.15 - 12.46
Beta	-0.30
Analysts	Hold
Price Target	7.00 (-7.16%)
Earnings Date	Mar 11, 2026

About NERV

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 1, 2014
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: NERV
• Website: https://www.minervaneurosciences.com

Analyst Summary

According to one analyst, the rating for NERV stock is "Hold" and the 12-month stock price target is $7.0.

Price Target

$7.0

(-7.16% downside)

Analyst Consensus: Hold